Live from the NIH registry
Studies recruiting near Reading right now
Top 25 of 271 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Lehigh Valley Hospital - Cedar Crest — Allentown, Pennsylvania (29.5 mi)
· Sponsor: American Society of Clinical Oncology
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Penn State Health Saint Joseph Medical Center — Reading, Pennsylvania (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
RA-PRO PRAGMATIC TRIAL
Rheumatoid Arthritis
Phase 3
Interventional 924 participants sought
PA Regional Center for Arthritis and Osteoporosis Research — Wyomissing, Pennsylvania (2.2 mi)
· Sponsor: University of Alabama at Birmingham
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania (29.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Bipolar Disorder, Bipolar Depression
Phase 3
Interventional 400 participants sought
Lehigh Center for Clinical Research — Allentown, Pennsylvania (29.5 mi)
· Sponsor: Xenon Pharmaceuticals Inc.
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2
Interventional 240 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi)
· Sponsor: NRG Oncology
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
Cardiology Associates of West Reading — West Reading, Pennsylvania (1.2 mi)
· Sponsor: Duke University
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: Eli Lilly and Company
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 750 participants sought
Lancaster General Hospital — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: Bristol-Myers Squibb
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
Phase 3
Interventional 1,056 participants sought
McGlinn Cancer Institute — West Reading, Pennsylvania (1.2 mi)
· Sponsor: BeOne Medicines
C-Brace Prospective Registry
Pareses, Lower Extremity
N/A
Observational 250 participants sought
Ability x Ottobock.care — Wyomissing, Pennsylvania (2.2 mi)
· Sponsor: Otto Bock Healthcare Products GmbH
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Multiple conditions
Phase 2
Interventional 98 participants sought
Ephrata Cancer Center — Ephrata, Pennsylvania (17.3 mi)
· Sponsor: NRG Oncology
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Phase 3
Interventional 1,000 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: Bristol-Myers Squibb
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Phase 3
Interventional 600 participants sought
Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania (1.2 mi)
· Sponsor: Hoffmann-La Roche
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
The Centers for Advanced Urology d/b/a Keystone Urology Specialist — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: Pfizer
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Phase 3
Interventional 1,750 participants sought
Clinical Trial Site — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: Alnylam Pharmaceuticals
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
Phase 3
Interventional 1,594 participants sought
Penn Medicine Lancaster General — Lancaster, Pennsylvania (28.9 mi)
· Sponsor: European Myeloma Network B.V.
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 335 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Penn State Health Saint Joseph Medical Center — Reading, Pennsylvania (0.3 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 626 participants sought
Local Institution - Unk041 — Allentown, Pennsylvania (29.5 mi)
· Sponsor: Mirati Therapeutics Inc.
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Phase 3
Interventional 410 participants sought
Local Institution - 1019 — Allentown, Pennsylvania (29.5 mi)
· Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Major Depressive Disorder
Phase 2
Interventional 164 participants sought
Lehigh Center for Clinical Research — Allentown, Pennsylvania (29.5 mi)
· Sponsor: Syndeio Biosciences, Inc
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Interventional 4,500 participants sought
US Digestive Health - Wyomissing — Wyomissing, Pennsylvania (2.2 mi)
· Sponsor: Eli Lilly and Company
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi)
· Sponsor: Novo Nordisk A/S